AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01396408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Description: 25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
Study NCT04375631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT04375631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04375631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV then PO
Study NCT04375631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT04375631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT04375631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT
Study NCT04375631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV
Study NCT04375631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT04375631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Sodium
Description: Given PO
Study NCT04375631 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04375631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT04375631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04375631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT04375631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04375631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study NCT04375631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspirate
Study NCT04375631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspirate
Study NCT04375631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03366740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GB mixed full strength rice suji
Description: On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
Study NCT03366740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full strength rice suji Alone
Description: On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
Study NCT03366740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3/4th strength rice suji
Description: On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
Study NCT01052597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
Study NCT01052597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcumin
Description: Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
Study NCT00538382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
Study NCT00538382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
Study NCT00950352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
Study NCT00950352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
Study NCT00700752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: silicone hydrogel contact lens
Study NCT00700752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: silicone hydrogel contact lens
Study NCT03761953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin Injection
Description: single 1200mg infusion of IV oritavancin.
Study NCT03138850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus standard bite block
Description: Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
Study NCT03138850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YX mandibular advancement bite block
Description: Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
Study NCT03138850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow High flow nasal cannula
Description: Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
Study NCT00649519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
Description: 10/20mg, single dose fasting
Study NCT00649519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrel® Capsules 10 mg/20 mg
Description: 10/20mg, single dose fasting
Study NCT00584103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beta P Experimental
Description: Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
Study NCT02345434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative letter
Description: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
Study NCT00279500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argus 16 Retinal Stimulation System
Description: The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
Study NCT01256619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
Study NCT04560296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based E-Health Program
Description: Community-based E-Health Program will be developed to engage and empower older adults to manage the chronic conditions effectively.
Study NCT00674336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Hydrostatic Pressure Processing
Description: High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
Study NCT03865407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
Study NCT01072864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Consumption of 5 g of walnuts.
Study NCT01072864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Consumption of 20 g of walnuts.
Study NCT01072864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Consumption of 30 g of walnuts.
Study NCT01072864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Consumption of 40 g of walnuts.
Study NCT04459299 — intervention group
Intervention type: DEVICE
Intervention: Robotic-PCI (CorPath GRX System)
Description: Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
Study NCT01524211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® t-Branch
Description: The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
Study NCT01524211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo Arch Branch
Description: The Arch Branch endograft is a custom-made endograft based on the Relay thoracic stent graft platform. The device is intended to land proximally in the ascending aorta just distal to the sinotubular junction, and distally either in the native thoracic aorta for focal arch pathologies, or more extensive pathologies either extended with another commercially available thoracic endograft or mated to a pre-existing thoracic endograft, which would serve as a distal landing zone. It is constructed of polyester graft material (same as those used for the Terumo Relay Plus or Pro) sewn to self-expanding nitinol stents with suture. The graft is fully stented to provide stability and the expansile force necessary to open the lumen of the graft during deployment. Additionally, the stents provide the necessary attachment and seal of the graft to the aortic wall.
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.15 mg kg-1
Description: Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide 0.3 mg kg-1
Description: Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 2.5 mg kg-1 was injected at I.V. line to patients
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 2.5 mg kg-1 was injected at I.V. line to patients
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol 2.5 mg kg-1 was injected at I.V. line to patients
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
Study NCT02467595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
Study NCT04479501 — intervention group
Intervention type: OTHER
Intervention: Asthma exacerbation related hospitalization
Description: Evaluate the difference between patients with single and multiple hospitalizations for asthma exacerbation
Study NCT01401088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial drainage implant
Description: Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
Study NCT02703116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Use BI
Description: Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
Study NCT02703116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Intervention
Description: Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
Study NCT02183545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: single rising doses given as tablet
Study NCT02183545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: given as tablet (matching placebo of BI 1060469)
Study NCT02052960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CetuGEX™
Description: 60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
Study NCT02052960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
Study NCT02052960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
Study NCT02052960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
Study NCT03879668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eIPOS
Description: Electronic version of IPOS
Study NCT02126644 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 70% glycolic acid
Study NCT02917486 — intervention group
Intervention type: OTHER
Intervention: blood sample
Study NCT01571882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit
Description: 1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
Study NCT01571882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit
Description: 2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
Study NCT01571882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)
Description: 3- Intervention with active control product (1,6 g of plant sterol/ day)
Study NCT02805907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol
Study NCT02805907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03059303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir 75 mg
Description: Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2.
Study NCT03059303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 25 mg
Description: Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2.
Study NCT03059303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 12.5 mg
Description: Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
Study NCT04560296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual self-management and follow up with doctors/nurse
Description: usual self-management and follow up with doctors/nurse as planned in the community nurse post.
Study NCT03448081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcipotriene
Description: Calcipotriene ointment (0.005%)
Study NCT03059303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 75 mg
Description: Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
Study NCT03448081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene
Description: Calcipotriene ointment (0.005%)
Study NCT03059303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335 800 mg
Description: Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2.
Study NCT03059303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Description: 30 mg lansoprazole once daily from Day 1 to Day 5.
Study NCT03059303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Description: 20 mg omeprazole once daily from Day 1 to Day 5.
Study NCT04330547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic administration
Description: * Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~* Level 2: Tramadol 50mg.~* Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~* Increase of a prior level 3 medication :~  1. 1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~ 2. If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)
Study NCT04330547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Folavit (folic acid, 0.4 mg)
Study NCT04425031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low oxygenation target
Description: Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
Study NCT04425031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High oxygenation target
Description: Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
Study NCT04797936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNO 1030
Description: Imupret 25 drops х 6 times per day for 14 days